Xenon Pharmaceuticals Inc.

Developing ion-channel modulators for epilepsy and neuropsychiatric disease, led by late-stage Kv7 opener azetukalner.

Back to company catalog

Neurology & neuropsychiatry · Ion-channel modulators · Phase 3 / NDA planned Q3 2026

Compare report options